These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

63 related items for PubMed ID: 19938151

  • 1. Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease.
    Lee SH, Kim MJ, Kim BJ, Kim SR, Chun S, Ryu JS, Kim GS, Lee MC, Koh JM, Chung SJ.
    Mov Disord; 2010 Feb 15; 25(3):332-40. PubMed ID: 19938151
    [Abstract] [Full Text] [Related]

  • 2. Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.
    Lee SH, Kim MJ, Kim BJ, Kim SR, Chun S, Kim HK, Ryu JS, Kim GS, Lee MC, Chung SJ, Koh JM.
    Calcif Tissue Int; 2010 Feb 15; 86(2):132-41. PubMed ID: 20049422
    [Abstract] [Full Text] [Related]

  • 3. Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women.
    Gerdhem P, Ivaska KK, Isaksson A, Pettersson K, Väänänen HK, Obrant KJ, Akesson K.
    J Bone Miner Res; 2007 Jan 15; 22(1):127-34. PubMed ID: 17032146
    [Abstract] [Full Text] [Related]

  • 4. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.
    Yuan RY, Sheu JJ, Yu JM, Hu CJ, Tseng IJ, Ho CS, Yeh CY, Hung YL, Chiang TR.
    J Neurol Sci; 2009 Dec 15; 287(1-2):64-8. PubMed ID: 19786283
    [Abstract] [Full Text] [Related]

  • 5. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
    Camicioli RM, Bouchard TP, Somerville MJ.
    Mov Disord; 2009 Jan 30; 24(2):176-82. PubMed ID: 18951534
    [Abstract] [Full Text] [Related]

  • 6. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep 30; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 7. Association of plasma folate, plasma total homocysteine, but not methylenetetrahydrofolate reductase C667T polymorphism, with bone mineral density in postmenopausal Iranian women: a cross-sectional study.
    Golbahar J, Hamidi A, Aminzadeh MA, Omrani GR.
    Bone; 2004 Sep 30; 35(3):760-5. PubMed ID: 15336613
    [Abstract] [Full Text] [Related]

  • 8. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
    Zoccolella S, dell'Aquila C, Abruzzese G, Antonini A, Bonuccelli U, Canesi M, Cristina S, Marchese R, Pacchetti C, Zagaglia R, Logroscino G, Defazio G, Lamberti P, Livrea P.
    Mov Disord; 2009 May 15; 24(7):1028-33. PubMed ID: 19353704
    [Abstract] [Full Text] [Related]

  • 9. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
    Bjøro K, Brandsaeter B, Wiencke K, Bjøro T, Godang K, Bollerslev J, Schrumpf E.
    Scand J Gastroenterol; 2003 Mar 15; 38(3):320-7. PubMed ID: 12737449
    [Abstract] [Full Text] [Related]

  • 10. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP.
    J Bone Miner Res; 2001 Jan 15; 16(1):104-12. PubMed ID: 11149473
    [Abstract] [Full Text] [Related]

  • 11. Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study.
    Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, Lamet I, Pagonabarraga J, Toledo JB, García-Garcia D, Clavero P, Samaranch L, Irurzun C, Matsubara JM, Irigoien J, Bescos E, Kulisevsky J, Pérez-Tur J, Obeso JA.
    Mov Disord; 2009 Jul 30; 24(10):1437-44. PubMed ID: 19452554
    [Abstract] [Full Text] [Related]

  • 12. Relationship between bone turnover and bone density at the proximal femur in stroke patients.
    Paker N, Bugdayci D, Tekdos D, Dere C, Kaya B.
    J Stroke Cerebrovasc Dis; 2009 Jul 30; 18(2):139-43. PubMed ID: 19251190
    [Abstract] [Full Text] [Related]

  • 13. [The effect of baseline homocysteine level on the efficacy of enalapril maleate and folic acid tablet in lowering blood pressure and plasma homocysteine].
    Zhao F, Li JP, Wang SY, Guan DM, Ge JB, Hu J, Wang YN, Zhang FM, Huo Y.
    Zhonghua Yi Xue Za Zhi; 2008 Nov 18; 88(42):2957-61. PubMed ID: 19080072
    [Abstract] [Full Text] [Related]

  • 14. Bone and mineral metabolism in older adults with Parkinson's disease.
    Abou-Raya S, Helmii M, Abou-Raya A.
    Age Ageing; 2009 Nov 18; 38(6):675-80. PubMed ID: 19684354
    [Abstract] [Full Text] [Related]

  • 15. Effect of folate supplementation on serum homocysteine and plasma total antioxidant capacity in hypercholesterolemic adults under lovastatin treatment: a double-blind randomized controlled clinical trial.
    Shidfar F, Homayounfar R, Fereshtehnejad SM, Kalani A.
    Arch Med Res; 2009 Jul 18; 40(5):380-6. PubMed ID: 19766902
    [Abstract] [Full Text] [Related]

  • 16. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 18; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 17. Folate supplementation does not affect biochemical markers of bone turnover.
    Herrmann M, Stanger O, Paulweber B, Hufnagl C, Herrmann W.
    Clin Lab; 2006 May 18; 52(3-4):131-6. PubMed ID: 16584059
    [Abstract] [Full Text] [Related]

  • 18. Serum homocysteine concentrations in children with growth hormone (GH) deficiency before and after 12 months GH replacement.
    Esposito V, Di Biase S, Lettiero T, Labella D, Simeone R, Salerno M.
    Clin Endocrinol (Oxf); 2004 Nov 18; 61(5):607-11. PubMed ID: 15521964
    [Abstract] [Full Text] [Related]

  • 19. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.
    Zhonghua Yi Xue Za Zhi; 2004 Feb 17; 84(4):269-73. PubMed ID: 15059505
    [Abstract] [Full Text] [Related]

  • 20. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov 17; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.